News | February 12, 2008

Trial To Test Radiation-Emitting Beads Against Advanced Liver Cancer

February 13, 2008 - Liver cancer specialists at Jefferson's Kimmel Cancer Center in Philadelphia are beginning an 18-month study of a new therapy for liver cancer that entails injecting tiny beads that emit small amounts of radiation into the liver's main artery while also blocking the blood supply feeding the cancer's growth.

The technique, called radioembolization, has been approved by the federal FDA for use in inoperable liver cancer. According to the hospital, this is the first time that the technology, called SIR-Spheres microspheres, which is FDA-approved for treating colon cancer that has spread to the liver, is being studied in patients with hepatocellular carcinoma, or primary liver cancer (cancer that originates in the liver). The trial, which is led by Brian Carr, M.D., FRCP, Ph.D., professor of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, includes patients from the University of Texas' M.D. Anderson Cancer Center in Houston and the University of Pittsburgh.

According to Dr. Carr, who is chief of the liver tumor program at the Kimmel Cancer Center and Thomas Jefferson University Hospital, the technique uses approximately 30-times more beads than other types or radioembolization. The teams plan to enroll 10 patients initially, and perhaps as many as 40 altogether.

"No one knows if radioembolization will be better than just radiation, even though there are theoretical grounds for it," Dr. Carr said.

In the form of radioembolization being tested, millions of tiny beads or "microspheres" containing the radioactive isotope Yttrium-90 are injected through a catheter directly into the liver's hepatic artery, which also supplies blood to tumors. The microspheres, in addition to blocking blood flow to the tumor, emit targeted radiation directly to the cancer, sparing healthy tissue.

Dr. Carr and his colleagues are encouraged by results from a recent clinical trial showing the effectiveness of a similar technique against advanced liver cancer. Reporting recently in the journal Hepatology, Dr. Carr and physicians at Northwestern University in Chicago found that injecting another type of Yttrium-90-containing beads (TheraSphere) was effective in treating inoperable liver cancer even in patients whose portal vein was blocked by tumor. The treatment, he said, was as good as or better than using the current standard called chemoembolization, which involves directly injecting chemotherapy drugs into the liver through the hepatic artery. Because it involves dangerous, cell-killing drugs, he noted, doctors have sought liver cancer treatments that have fewer toxic effects.

The treatment doesn't cure the cancer, but has been shown to often shrink tumors and help patients live longer, said Dr. Carr. It can also be used for patients who have previously failed chemotherapy.

For more information: www.jeffersonhospital.org

Related Content

First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init